Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
CH3CONHOH
CAS Number:
Molecular Weight:
75.07
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
1739019
grade
pharmaceutical primary standard
API family
acetohydroxamic acid
manufacturer/tradename
USP
mp
88-90 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CC(NO)=O
InChI
1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
InChI key
RRUDCFGSUDOHDG-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Acetohydroxamic acid USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Acetohydroxamic Acid Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Acetohydroxamic acid
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Raymond L Benza et al.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 34(3), 329-337 (2014-07-08)
Pulmonary hypertension (PH) associated with left heart disease (World Health Organization [WHO] Group II) has previously been linked with significant morbidity and mortality. However, there are currently no approved therapies or hemodynamic monitoring systems to improve outcomes in WHO Group
Saro H Armenian et al.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 23(6), 1109-1114 (2014-04-11)
Childhood cancer survivors are at high risk of developing congestive heart failure (CHF) compared with the general population, and there is a dose-dependent increase in CHF risk by anthracycline dose. The mechanism by which this occurs has not been fully
Baris Gencer et al.
Atherosclerosis, 239(1), 118-124 (2015-01-15)
2013 AHA/ACC guidelines on the treatment of cholesterol advised to tailor high-intensity statin after ACS, while previous ATP-III recommended titration of statin to reach low-density lipoprotein cholesterol (LDL-C) targets. We simulated the impact of this change of paradigm on the